Developer docs
API playgroundTry for free, no card

Search company profiles

InCarda Therapeutics

Full company profile

uuid0000lcq

Namestring
InCarda Therapeutics
Legal namestring
InCarda Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2009
Descriptiontext

InCarda Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2009 and headquartered in West Jordan, Utah, with a wholly-owned Australian subsidiary in Melbourne. The company is developing novel pharmacological therapies for cardioversion of paroxysmal atrial fibrillation (AF) and atrial flutter (AFL), targeting rapid and safe restoration of normal sinus rhythm. Its core technology pairs Class I-C and Class III antiarrhythmic agents in a synergistic combination designed to maximize cardioversion rates while reducing proarrhythmic risk compared to single-agent therapy. The pipeline consists of two lead programs: an intravenous (IV) Fixed Dose Combination for medically supervised hospital cardioversion, currently in a planned Phase 1 study to confirm safety, PK/PD, and reduced proarrhythmic risk; and a Home Cardioversion Program for self-administered at-home use, currently in preclinical development.

InCarda's go-to-market strategy is structured around two distinct care settings. In the hospital channel, the IV Fixed Dose Combination is positioned for inpatient and outpatient cardioversion, distributed via hospital formularies and pharmacy channels upon regulatory approval. In the at-home channel, the company is developing a self-administered therapy intended to enable earlier discharge, reduce hospital burden, and expand treatment access. The company engages with healthcare providers through medical publications, cardiology conferences, and direct clinical operations outreach rather than consumer marketing. Future revenue is expected to derive from FDA-approved pharmaceutical products sold to hospital systems and, potentially, dispensed directly to eligible patients for at-home use.

The company is venture-backed, having raised approximately $77.9 million across multiple funding rounds between 2012 and 2020, with investors including Innoviva, Deerfield Management, OrbiMed, HealthCap, Sofinnova Partners, Morningside Private Investors, AMV, and 5Y Capital. Leadership comprises a CEO (Dr. Myles Greenberg), CMO (Dr. Luiz Belardinelli), CFO (Carol Manchester, CPA), CTO (Carlos Schuler, PhD), and CBO (Narsi Rangachari), supported by dedicated heads of Regulatory, Clinical Operations, and CMC. InCarda remains pre-revenue with no approved products, and its primary value drivers are clinical trial readouts and eventual regulatory milestones rather than current commercial sales.

Short descriptiontext

InCarda Therapeutics is a clinical-stage biopharmaceutical company developing synergistic Class I-C and Class III antiarrhythmic drug combinations for rapid cardioversion of paroxysmal atrial fibrillation and atrial flutter, with an IV hospital program in Phase 1 and a preclinical at-home self-administration program.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWest Jordan, United States
HQ citystring
West Jordan
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
atrial fibrillation therapy, antiarrhythmic drug development, cardioversion pharmaceuticals, inhaled cardiovascular drugs, hospital cardiac therapeutics
Industry1 code
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cardiovascular Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-revenue biopharmaceutical company developing novel atrial fibrillation cardioversion therapies. Revenue will be generated from FDA-approved pharmaceutical products for hospital-based and at-home cardioversion treatment once clinical development is completed.

incardatherapeutics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

InCarda Therapeutics is a clinical-stage biopharmaceutical company developing prescription drug therapies for atrial fibrillation (AFib) and atrial flutter (AFL) cardioversion. Its pipeline centers on a synergistic combination of Class I-C and Class III antiarrhythmic agents delivered as an IV fixed-dose combination for hospital cardioversion and as an at-home self-administered therapy, designed to restore normal sinus rhythm rapidly while reducing proarrhythmic risk.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Maximizes cardioversion rates in paroxysmal AFib and AFL
+3 more records
Product overview1 text field

InCarda Therapeutics is developing a pipeline of innovative drug therapies for atrial fibrillation treatment, consisting of two core product candidates: an IV Fixed Dose Combination for medically supervised hospital cardioversion (currently in Phase 1 clinical development) and a Home Cardioversion Program for at-home self-administration (currently in preclinical development). Both products leverage synergistic combinations of Class I-C and Class III antiarrhythmic drugs to restore normal sinus rhythm, with the hospital program targeting inpatient and outpatient settings while the home program expands treatment access beyond clinical environments.

Product and service2 records
1IV Fixed Dose Combination (In-Hospital Cardioversion Therapy)
CategoryPrescription pharmaceutical (antiarrhythmic)
Description

Intravenous fixed-dose combination therapy pairing Class I-C and Class III antiarrhythmics for rapid, safe, and effective cardioversion of paroxysmal atrial fibrillation and atrial flutter in medically supervised hospital settings. Currently in Phase 1 clinical development.

2Home Cardioversion Program (At-Home Self-Administered Therapy)
CategoryPrescription pharmaceutical (antiarrhythmic)
Description

Self-administered antiarrhythmic therapy designed to enable patients to convert atrial fibrillation to normal sinus rhythm at home without leaving their residence, expanding treatment access beyond clinical environments. Currently in preclinical development.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1AnGes MG
TypeEmerging player
Description

Clinical-stage Japanese biopharma developing cardiovascular therapies including gene-based approaches. Comparable as a small, cardiovascular-focused clinical developer.

2Acesion Pharma
TypeDirect peer
Description

Denmark-based clinical-stage company developing SK channel inhibitors for atrial fibrillation. Comparable as a focused, venture-backed AFib antiarrhythmic developer.

TypeEmerging player
Description

Clinical-stage cell therapy company with cardiovascular programs. Comparable as a small, clinical-stage cardiovascular developer pursuing novel mechanisms.

4Correvio Pharma (now AOP Orphan Pharmaceuticals)
TypeDirect peer
Description

Specialty cardiovascular company that commercialized Brinavess (vernakalant), an IV antiarrhythmic for rapid AFib cardioversion. Closest precedent for an IV pharmacologic AFib cardioversion launch.

5Espero BioPharma
TypeEmerging player
Description

Emerging cardiovascular pharmaceutical company developing therapies for atrial fibrillation and other cardiovascular conditions. Comparable as a smaller, AFib-focused clinical-stage peer.

6Armaron Bio
TypeEmerging player
Description

Australia-based clinical-stage company developing cardioprotective therapies, including approaches targeting AFib. Comparable as a small, Australia-affiliated cardiovascular developer.

TypeEmerging player
Description

Clinical-stage company developing small-molecule omega-3 epoxyeicosanoid analogs for cardiovascular indications including AFib. Comparable in therapeutic area and clinical maturity.

TypeDirect peer
Description

Clinical-stage company developing etripamil, a nasal spray calcium channel blocker for rapid cardioversion of PSVT and potentially AFib. Direct peer in the antiarrhythmic, patient-administered cardioversion space.

TypeEmerging player
Description

Clinical-stage company developing FDY-5301 for cardiac protection and indications including AFib. Comparable as a venture-backed cardiovascular developer in similar clinical stage.

TypeBroad incumbent
Description

Broader biopharma company with cardiovascular programs and global development partnerships. Comparable as a cardiovascular-focused specialty pharma, though operating at a wider portfolio level.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles24 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InCarda Therapeutics

Cardiovascular Pharmaceuticalsincardatherapeutics.com

InCarda Therapeutics is a clinical-stage biopharmaceutical company developing synergistic Class I-C and Class III antiarrhythmic drug combinations for rapid cardioversion of paroxysmal atrial fibrillation and atrial flutter, with an IV hospital program in Phase 1 and a preclinical at-home self-administration program.

What InCarda Therapeutics does

InCarda Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2009 and headquartered in West Jordan, Utah, with a wholly-owned Australian subsidiary in Melbourne. The company is developing novel pharmacological therapies for cardioversion of paroxysmal atrial fibrillation (AF) and atrial flutter (AFL), targeting rapid and safe restoration of normal sinus rhythm. Its core technology pairs Class I-C and Class III antiarrhythmic agents in a synergistic combination designed to maximize cardioversion rates while reducing proarrhythmic risk compared to single-agent therapy. The pipeline consists of two lead programs: an intravenous (IV) Fixed Dose Combination for medically supervised hospital cardioversion, currently in a planned Phase 1 study to confirm safety, PK/PD, and reduced proarrhythmic risk; and a Home Cardioversion Program for self-administered at-home use, currently in preclinical development.

InCarda's go-to-market strategy is structured around two distinct care settings. In the hospital channel, the IV Fixed Dose Combination is positioned for inpatient and outpatient cardioversion, distributed via hospital formularies and pharmacy channels upon regulatory approval. In the at-home channel, the company is developing a self-administered therapy intended to enable earlier discharge, reduce hospital burden, and expand treatment access. The company engages with healthcare providers through medical publications, cardiology conferences, and direct clinical operations outreach rather than consumer marketing. Future revenue is expected to derive from FDA-approved pharmaceutical products sold to hospital systems and, potentially, dispensed directly to eligible patients for at-home use.

The company is venture-backed, having raised approximately $77.9 million across multiple funding rounds between 2012 and 2020, with investors including Innoviva, Deerfield Management, OrbiMed, HealthCap, Sofinnova Partners, Morningside Private Investors, AMV, and 5Y Capital. Leadership comprises a CEO (Dr. Myles Greenberg), CMO (Dr. Luiz Belardinelli), CFO (Carol Manchester, CPA), CTO (Carlos Schuler, PhD), and CBO (Narsi Rangachari), supported by dedicated heads of Regulatory, Clinical Operations, and CMC. InCarda remains pre-revenue with no approved products, and its primary value drivers are clinical trial readouts and eventual regulatory milestones rather than current commercial sales.

InCarda Therapeutics firmographics

Firmographics
Name
InCarda Therapeutics
Legal name
InCarda Therapeutics, Inc.
Website
https://incardatherapeutics.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
InCarda Therapeutics is a clinical-stage biopharmaceutical company developing synergistic Class I-C and Class III antiarrhythmic drug combinations for rapid cardioversion of paroxysmal atrial fibrillation and atrial flutter, with an IV hospital program in Phase 1 and a preclinical at-home self-administration program.
Ownership category
akta.pro rank

InCarda Therapeutics industry classification

Industry
Product category
Cardiovascular Pharmaceuticals
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Atrial fibrillation therapy
  • Antiarrhythmic drug development
  • Cardioversion pharmaceuticals
  • Inhaled cardiovascular drugs
  • Hospital cardiac therapeutics

Where InCarda Therapeutics is headquartered

Location

Headquarters

HQ city
West Jordan
HQ country
United States
HQ region
North America

Offices2 records

Markets served

InCarda Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Revenue: Pre-revenue biopharmaceutical company developing novel atrial fibrillation cardioversion therapies. Revenue will be generated from FDA-approved pharmaceutical products for hospital-based and at-home cardioversion treatment once clinical development is completed.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

InCarda Therapeutics product offering

Product offering

Core offering

InCarda Therapeutics is a clinical-stage biopharmaceutical company developing prescription drug therapies for atrial fibrillation (AFib) and atrial flutter (AFL) cardioversion. Its pipeline centers on a synergistic combination of Class I-C and Class III antiarrhythmic agents delivered as an IV fixed-dose combination for hospital cardioversion and as an at-home self-administered therapy, designed to restore normal sinus rhythm rapidly while reducing proarrhythmic risk.

Product overview

InCarda Therapeutics is developing a pipeline of innovative drug therapies for atrial fibrillation treatment, consisting of two core product candidates: an IV Fixed Dose Combination for medically supervised hospital cardioversion (currently in Phase 1 clinical development) and a Home Cardioversion Program for at-home self-administration (currently in preclinical development). Both products leverage synergistic combinations of Class I-C and Class III antiarrhythmic drugs to restore normal sinus rhythm, with the hospital program targeting inpatient and outpatient settings while the home program expands treatment access beyond clinical environments.

Differentiator

Problem solved

Functional benefit

Products and services

  • IV Fixed Dose Combination (In-Hospital Cardioversion Therapy) Intravenous fixed-dose combination therapy pairing Class I-C and Class III antiarrhythmics for rapid, safe, and effective cardioversion of paroxysmal atrial fibrillation and atrial flutter in medically supervised hospital settings. Currently in Phase 1 clinical development.
  • Home Cardioversion Program (At-Home Self-Administered Therapy) Self-administered antiarrhythmic therapy designed to enable patients to convert atrial fibrillation to normal sinus rhythm at home without leaving their residence, expanding treatment access beyond clinical environments. Currently in preclinical development.

Quantifiable outcome

  • Maximizes cardioversion rates in paroxysmal AFib and AFL
  • +3 more outcomes

Companies that use InCarda Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

InCarda Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

InCarda Therapeutics partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

InCarda Therapeutics competitors and assessment

Company assessment

Emerging players

  • AnGes MG: Clinical-stage Japanese biopharma developing cardiovascular therapies including gene-based approaches. Comparable as a small, cardiovascular-focused clinical developer.
  • BioCardia: Clinical-stage cell therapy company with cardiovascular programs. Comparable as a small, clinical-stage cardiovascular developer pursuing novel mechanisms.
  • Espero BioPharma: Emerging cardiovascular pharmaceutical company developing therapies for atrial fibrillation and other cardiovascular conditions. Comparable as a smaller, AFib-focused clinical-stage peer.
  • Armaron Bio: Australia-based clinical-stage company developing cardioprotective therapies, including approaches targeting AFib. Comparable as a small, Australia-affiliated cardiovascular developer.
  • Omeicos Therapeutics: Clinical-stage company developing small-molecule omega-3 epoxyeicosanoid analogs for cardiovascular indications including AFib. Comparable in therapeutic area and clinical maturity.
  • Faraday Pharmaceuticals: Clinical-stage company developing FDY-5301 for cardiac protection and indications including AFib. Comparable as a venture-backed cardiovascular developer in similar clinical stage.

Direct peers

  • Acesion Pharma: Denmark-based clinical-stage company developing SK channel inhibitors for atrial fibrillation. Comparable as a focused, venture-backed AFib antiarrhythmic developer.
  • Correvio Pharma (now AOP Orphan Pharmaceuticals): Specialty cardiovascular company that commercialized Brinavess (vernakalant), an IV antiarrhythmic for rapid AFib cardioversion. Closest precedent for an IV pharmacologic AFib cardioversion launch.
  • Milestone Pharmaceuticals: Clinical-stage company developing etripamil, a nasal spray calcium channel blocker for rapid cardioversion of PSVT and potentially AFib. Direct peer in the antiarrhythmic, patient-administered cardioversion space.

Broad incumbents

  • HUYA Bioscience International: Broader biopharma company with cardiovascular programs and global development partnerships. Comparable as a cardiovascular-focused specialty pharma, though operating at a wider portfolio level.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

InCarda Therapeutics social profiles

Digital presence

InCarda Therapeutics compliance and trust

Trust signal

Compliance1 record

InCarda Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InCarda Therapeutics leadership team

Management profile

Number of profiles

Profiles24 records

InCarda Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

InCarda Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InCarda Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InCarda Therapeutics

What does InCarda Therapeutics do?

InCarda Therapeutics is a clinical-stage biopharmaceutical company developing prescription drug therapies for atrial fibrillation (AFib) and atrial flutter (AFL) cardioversion. Its pipeline centers on a synergistic combination of Class I-C and Class III antiarrhythmic agents delivered as an IV fixed-dose combination for hospital cardioversion and as an at-home self-administered therapy, designed to restore normal sinus rhythm rapidly while reducing proarrhythmic risk.

Is InCarda Therapeutics a public or private company?

InCarda Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was InCarda Therapeutics founded?

InCarda Therapeutics was founded in 2009. It employs 11 to 50 people.

Where is InCarda Therapeutics based?

InCarda Therapeutics is headquartered in West Jordan, United States, in the North America region.

How does InCarda Therapeutics make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are InCarda Therapeutics's main competitors?

Emerging players on record are AnGes MG, BioCardia, Espero BioPharma, Armaron Bio, Omeicos Therapeutics and Faraday Pharmaceuticals. Direct peers are Acesion Pharma, Correvio Pharma (now AOP Orphan Pharmaceuticals) and Milestone Pharmaceuticals. HUYA Bioscience International is listed as a broad incumbent.

Does InCarda Therapeutics have an API?

No public API is recorded for InCarda Therapeutics.

What industry is InCarda Therapeutics in?

InCarda Therapeutics's product category is Cardiovascular Pharmaceuticals. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venture Capital Access OnlineInCarda Therapeutics Raises $30 Million Through First Close of Series C Equity FinancingInCarda Therapeutics raised $30 million in the first close of its Series C equity financing, led by an affiliate of Innoviva with participation from Deerfield Management, HealthCap, and Morningside Venture. The funds will support the ongoing clinical development of InRhythm, an inhaled antiarrhythmic candidate for paroxysmal atrial fibrillation, as the company prepares to present positive Phase 2 data and initiate pivotal Phase 3 trials.Business Wire BlogCORRECTING and REPLACING InCarda Therapeutics Appoints Dr. Myles Greenberg as New CEOInCarda Therapeutics appointed Dr. Myles Greenberg as its new president and CEO, succeeding interim CEO Carlos Schuler who will transition to chief technology officer. The leadership change occurs as the clinical-stage biopharmaceutical company advances the development of FlecIH-103, an orally inhaled treatment for atrial fibrillation. Dr. Greenberg brings nearly 25 years of experience in life-sciences business growth and product development to the role.ClinicaltrialvanguardInCarda Phase 3 Trial Prematurely TerminatedInCarda Therapeutics prematurely terminated its Phase 3 RESTORE-1 trial for FlecIH-103, an inhaled solution for paroxysmal atrial fibrillation, due to low enrollment. Despite the termination, the study demonstrated that the drug achieved a statistically significant cardioversion rate of 31% and reduced the need for electrical cardioversion. The company is now transitioning to a new drug-delivery platform supported by earlier clinical data to advance the therapy.GlobeNewswireInCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate GrowthInCarda Therapeutics appointed Robert Lisicki as CEO and board member, replacing Grace E. Colón, who will serve as consultant. The transition supports the company's shift toward commercial activities and potential public market access. Lisicki brings over 25 years of commercial experience, including roles at Arena Pharmaceuticals and Regeneron.NationalacademiesBack ButtonA National Academies workshop report on innovation in drug research for prevalent chronic diseases summarized presentations by FDA, InCarda Therapeutics, NIH's BRAIN Initiative and twoXAR Pharmaceuticals. Speakers covered targeted therapies, multi-omics and radiomics data, model-informed drug development, AI-driven discovery, and digital health tools for clinical trials.GlobeNewswireInCarda Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for InRhythm™ for Treatment of Atrial FibrillationInCarda Therapeutics completed an End-of-Phase 2 meeting with the FDA for InRhythm, an inhaled flecainide for atrial fibrillation. The FDA agreed a single Phase 3 trial of 400 patients will support an NDA filing. The company plans to initiate the RESTORE1 trial in Q3 2021, with data expected in H2 2022.VC News DailyInCarda Therapeutics Raises $30M in Series CInCarda Therapeutics, a privately-held biopharmaceutical company, has raised $30 million through the first close of a Series C equity financing. The round was led by an affiliate of Innoviva, Inc., with participation from existing investors Deerfield Management, HealthCap, and Morningside Ventures. Proceeds will fund the clinical development of InRhythm, the company's inhaled flecainide therapy for treating recent-onset paroxysmal atrial fibrillation.FierceBiotechInCarda raises $30M to reimagine afib treatment with drug-device comboInCarda Therapeutics has raised $30 million in Series C funding to advance the development of InRhythm, an inhalable flecainide treatment for atrial fibrillation. The company is collaborating with Trudell Medical International to produce portable nebulizers for this drug-device combination and is currently recruiting for phase 2 trials while preparing for phase 3 studies.MobiHealthNewsDigital's future in respiratory health, from clinical trials to remote carePanelists at the BIO Digital conference discussed the integration of digital tools and telemedicine to manage respiratory conditions like asthma and COPD, highlighting current obstacles in measurement and infrastructure. Key companies including Sanofi, ResMed, and InCarda Therapeutics are exploring these technologies to improve patient monitoring and clinical trial efficiency amidst challenges related to health disparities.GlobeNewswireInCarda Therapeutics Appoints Daniel G. Welch as Executive Chairman of Board of DirectorsInCarda Therapeutics appointed Daniel G. Welch as executive chairman of its board, effective March 7, 2019. Welch previously led AveXis, InterMune, and Triangle Pharmaceuticals, and now chairs Ultragenyx and Levo Therapeutics. The company is advancing its InRhythm inhaled therapy for atrial fibrillation.